Matthew Gitlin

2.4k total citations · 1 hit paper
79 papers, 1.7k citations indexed

About

Matthew Gitlin is a scholar working on Nephrology, Oncology and Hematology. According to data from OpenAlex, Matthew Gitlin has authored 79 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Nephrology, 19 papers in Oncology and 17 papers in Hematology. Recurrent topics in Matthew Gitlin's work include Erythropoietin and Anemia Treatment (16 papers), Dialysis and Renal Disease Management (15 papers) and Hip and Femur Fractures (12 papers). Matthew Gitlin is often cited by papers focused on Erythropoietin and Anemia Treatment (16 papers), Dialysis and Renal Disease Management (15 papers) and Hip and Femur Fractures (12 papers). Matthew Gitlin collaborates with scholars based in United States, Switzerland and United Kingdom. Matthew Gitlin's co-authors include Carly J. Paoli, Mark A. Reynolds, Elliott D. Crouser, Meenal Sinha, Susan Shepherd, Andy Nguyen, Karen Chung, Tracy J. Mayne, Nick Freemantle and Cyrus Cooper and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Matthew Gitlin

77 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level*

2018 464 citations Carly J. Paoli, Mark A. Reynolds et al. Critical Care Medicine profile →

Peers

Countries citing papers authored by Matthew Gitlin

Since Specialization

Citations

This map shows the geographic impact of Matthew Gitlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Gitlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Gitlin more than expected).

Fields of papers citing papers by Matthew Gitlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Gitlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Gitlin. The network helps show where Matthew Gitlin may publish in the future.

Co-authorship network of co-authors of Matthew Gitlin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Gitlin. A scholar is included among the top collaborators of Matthew Gitlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Gitlin. Matthew Gitlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials 2023 ·Blood ·(unknown), Matthew Gitlin, Abraham P. Lee, (unknown), Victoria Barghout, (unknown)	1
2	A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy 2022 ·Transplantation and Cellular Therapy ·(unknown), Matthew Gitlin, (unknown)	3
3	Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in China: a simulation projection model from 2020 to 2040 2021 ·Archives of Osteoporosis ·Lijia Cui, (unknown), (unknown), Matthew Gitlin, Weibo Xia	22
4	Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in Japan: a simulation projection model from 2020 to 2040 2021 ·Archives of Osteoporosis ·Hiroshi Hagino, (unknown), Matthew Gitlin, (unknown)	4
5	PND40 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN 2019 ·Value in Health ·Matthew Gitlin, Susan M. Snyder, (unknown)	1
6	PND19 CLINICAL AND ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN EUROPE 2019 ·Value in Health ·(unknown), (unknown), Susan M. Snyder, Matthew Gitlin	1
7	PND11 ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS OTHER DISEASE MODYFING THERAPIES IN PUBLICLY INSURED BRAZILIAN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS 2019 ·Value in Health Regional Issues ·(unknown), (unknown), (unknown), (unknown), Susan M. Snyder, Matthew Gitlin	1
8	A Systematic Review of the Health Economics of Pompe Disease 2019 ·PharmacoEconomics - Open ·Benedikt Schoser, Andreas Hahn, Emma S. James, Digant Gupta, Matthew Gitlin, Suyash Prasad	12
9	Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level* breakdown → 2018 ·Critical Care Medicine ·Carly J. Paoli, Mark A. Reynolds, Meenal Sinha, Matthew Gitlin, Elliott D. Crouser	464
10	PND33 - PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY 2018 ·Value in Health ·(unknown), (unknown), Matthew Gitlin, (unknown)	1
11	Geographic Disparities in Patient Travel for Dialysis in the United States 2013 ·The Journal of Rural Health ·(unknown), (unknown), Stephan Dunning, (unknown), David T. Gilbertson, David J. Harrison, (unknown), Ann C. McClellan, William M. McClellan, Shaowei Wan, Matthew Gitlin	43
12	Clinical Factors and the Decision to Transfuse Chronic Dialysis Patients 2013 ·Clinical Journal of the American Society of Nephrology ·Cynthia B. Whitman, Sanatan Shreay, Matthew Gitlin, Martijn G.H. van Oijen, Brennan Spiegel	20
13	Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study 2013 ·Osteoporosis International ·Françis Guillemin, L. Martínez, Melanie Calvert, Cyrus Cooper, Théodore G. Ganiats, Matthew Gitlin, Robert Horne, (unknown), Johannes Pfeilschifter, Susan Shepherd, Anna N.A. Tosteson, Sally W. Wade, David Macarios, Nick Freemantle	47
14	Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom 2012 ·Bone ·Lia Gutiérrez, Neil Roskell, Jordi Castellsagué, (unknown), Catherine Rycroft, (unknown), (unknown), Matthew Gitlin, Sean Robbins	22
15	Electronic medical records: a survey of use and satisfaction in small dialysis organizations. 2011 ·PubMed ·(unknown), Matthew Gitlin, (unknown), (unknown), Tracy J. Mayne	3
16	Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom 2011 ·Journal of Medical Economics ·Lia Gutiérrez, Neil Roskell, Jordi Castellsagué, S Beard, Catherine Rycroft, (unknown), (unknown), Sean Robbins, Matthew Gitlin	33
17	Systematic Review and Meta-analysis of Exercise Tolerance and Physical Functioning in Dialysis Patients Treated With Erythropoiesis-Stimulating Agents 2010 ·American Journal of Kidney Diseases ·Kirsten L. Johansen, Fredric O. Finkelstein, Dennis A. Revicki, Matthew Gitlin, Chris Evans, Tracy J. Mayne	58
18	Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU® study 2010 ·Osteoporosis International ·Christian Roux, Cyrus Cooper, Adolfo Díez‐Pérez, L. Martínez, S. Ortolani, Matthew Gitlin, (unknown), Susan Shepherd, Nick Freemantle	11
19	Identifying Best Practices in Dialysis Care 2008 ·Clinical Journal of the American Society of Nephrology ·Amar A. Desai, Roger Bolus, Allen R. Nissenson, (unknown), Matthew D. Solomon, Osman Khawar, Matthew Gitlin, Jennifer Talley, Brennan Spiegel	32
20	New workers' compensation legislation: Expected pharmaceutical cost savings 2005 ·American Journal of Industrial Medicine ·Leslie Wilson, Matthew Gitlin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact